NEW YORK, June 30, 2014 /PRNewswire/ --
Today, Analysts Review released its analysts' notes regarding Tenet Healthcare Corp (NYSE: THC), Hologic, Inc. (NASDAQ: HOLX), PAREXEL International Corporation (NASDAQ: PRXL), Centene Corp (NYSE: CNC) and Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/4251-100free.
--
Tenet Healthcare Corp Analyst Notes
On June 25, 2014, Tenet Healthcare Corp (Tenet) announced that it has completed its previously announced private offering of $500 million aggregate principal amount of 5% senior notes due 2019, issued on March 10, 2014. According to the Company, the proceeds from the offering will be used to redeem Tenet's 9.25% senior notes due 2015 as well as to pay for related transaction fees and expenses. The full analyst notes on Tenet are available to download free of charge at:
http://www.analystsreview.com/Jun-30-2014/THC/report.pdf
--
Hologic, Inc. Analyst Notes
On June 24, 2014, Hologic, Inc. (Hologic) announced that a study published in the June 25, 2014 issue of the Journal of the American Medical Association found that the Company's 3D Mammography screening technology identifies more invasive cancers versus traditional mammograms. According to the Company, the study, named the "Breast Cancer Screening Using Tomosynthesis in Combination with Digital Mammography", showed that 3D mammography reduces the number of women called back for testing due to false alarms, resulting in reduced anxiety and saved health care costs. Hologic added that a total of 454,850 examinations (281,187 conventional mammograms compared to 173,663 3D mammography exams) were included in the study. The said study was led by Sarah M. Friedewald, MD of the Caldwell Breast Center, Advocate Lutheran General Hospital in Park Ridge, Illinois. The full analyst notes on Hologic are available to download free of charge at:
http://www.analystsreview.com/Jun-30-2014/HOLX/report.pdf
--
PAREXEL International Corporation Analyst Notes
On June 23, 2014, PAREXEL International Corporation (PAREXEL) announced that it has been named the 2014 Best Performing CRO in Taiwan award from the Foundation of Medical Professionals Alliance in Taiwan (FMPAT) during the Taiwan Biotechnology Trend and Challenges Conference held in May 2014. The Company was recognized for its innovative drug development strategies and healthcare industry leadership. Commenting on the recognition, Albert Liou, Vice Chairman of PAREXEL Asia Pacific said, "PAREXEL applies its scientific expertise and innovative approaches to reducing clinical trial complexity to help create greater opportunities for clinical research in Taiwan and across the region. We appreciate this recognition of our ongoing commitment to simplifying drug development for our customers and supporting their efforts to prevent and cure disease." The full analyst notes on PAREXEL are available to download free of charge at:
http://www.analystsreview.com/Jun-30-2014/PRXL/report.pdf
--
Centene Corp Analyst Notes
On June 18, 2014, Centene Corp (Centene) announced that Sunflower Health Plan, a wholly-owned Kansas subsidiary of the Company, has received Accreditation from the National Committee for Quality Assurance (NCQA). According to the Company, the NCQA Health Plan Accreditation evaluates a health plan's management of all parts of its delivery system including its physicians, hospital, as well as other providers and administrative services, in order to continuously improve the quality of care and services it provide to its members. Dr. Michael D. McKinney, Plan President and CEO of Sunflower Health Plan said, "We are honored to be presented the certificate of Accreditation from NCQA, as the process allowed the Sunflower team of 300 employees to identify performance improvement opportunities as well as build and strengthen relationships with the communities we serve." The full analyst notes on Centene are available to download free of charge at:
http://www.analystsreview.com/Jun-30-2014/CNC/report.pdf
--
Alnylam Pharmaceuticals, Inc. Analyst Notes
On June 19, 2014, Alnylam Pharmaceuticals, Inc. (Alnylam) and The Alpha-1 Project (TAP), the venture philanthropy subsidiary of the Alpha-1 Foundation, announced that they have entered into a collaboration agreement to continue the advancement of ALN-AAT, a subcutaneously administered RNAi therapeutic in development for the treatment of alpha-1 antitrypsin (AAT) deficiency-associated liver disease. According to the Company, TAP's mission is to work with patients, the academe, pharmaceutical and biotech companies, and public health organizations to find cures and therapies for chronic obstructive pulmonary disease (COPD) and liver disease caused by AAT deficiency. TAP is partially funding research activities for ALN-AAT, and Alnylam expects to file an investigational new drug (IND) application for this program in mid-2015. The full analyst notes on Alnylam are available to download free of charge at:
http://www.analystsreview.com/Jun-30-2014/ALNY/report.pdf
--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.
===============
EDITOR'S NOTES:
===============
1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.
5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
AnalystsReview.com
SOURCE Analysts Review
